stockrow
Friday 6 November 2026
Export LAB’s income statement to Excel — free account
Standard BioTools Inc.
LAB Healthcare Medical Devices
Standard BioTools Inc.’s revenue for fiscal 2025 (year ended December 2025) was $85.3 million, down 6.24% from fiscal 2024.
- Revenue
- −0.85%
- EPS
- +138.1%
- Free cash flow
- +73.3%
- Total debt
- +0.33%
Quarter to September 2026, against a year earlier
0.63
0.01
+1.61%
Follow LAB
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
2.15 | 3.73 | 4.60 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.45 | 3.79 | 4.14 | 5.72 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(47.27) | (31.09) | (7.66) | (410.49) | |
P/B ratio |
0.52 | 0.59 | 0.64 | 1.15 | |
Price to Tangible BV |
0.70 | 0.80 | 0.85 | 1.72 | |
EV/Sales |
(1.95) | (1.78) | (1.08) | 3.59 | |
EV/EBITDA |
2.04 | 1.62 | 1.03 | 0.00 | |
EV/Operating CF |
2.56 | 1.88 | 1.02 | (4.12) | |
EV/FCF |
2.28 | 1.69 | 0.92 | (3.43) | |
Quick Ratio |
9.29 | 8.67 | 11.77 | 1.86 | |
Current Ratio |
9.75 | 9.10 | 12.36 | 4.19 | |
Net Debt/EBITDA |
23.31 | 18.81 | 38.81 | 7.86 | |
Debt/Assets |
0.05% | 0.05% | 0.05% | 0.05% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.14 | 0.14 | 0.14 | 0.14 | |
Operating CF/Net income |
(0.46) | 0.39 | (0.37) | (0.06) | |
Capex/Depreciation |
0.00 | (5.21) | (0.73) | (0.57) | |
Interest Coverage |
— | — | — | (1,540.25) | |
Research and Development Expense of Revenue |
10.72% | 9.83% | 10.01% | 33.49% | |
Selling, General and Administrative Expense of Revenue |
86.89% | 81.52% | 87.99% | 106.48% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
19.21% | 20.15% | 41.73% | 24.14% | |
Graham Net Nets |
1.43 | 1.34 | 1.24 | 0.64 | |
Graham Number |
3.31 | 2.62 | 2.55 | 0.00 | |
Earnings Yield |
46.53% | 26.83% | 21.74% | (15.63%) | |
Free Cash Flow Yield |
(24.81%) | (27.82%) | (28.30%) | (18.27%) | |
Revenue per Share |
0.05 | 0.05 | 0.05 | 0.06 | |
Operating CF per Share |
(0.02) | (0.03) | (0.12) | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.02) | (0.03) | (0.12) | 0.00 | |
Cash per Share |
1.17 | 1.22 | 1.17 | 0.49 | |
Shareholders Equity per Share |
1.41 | 1.38 | 1.45 | 1.11 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.41 | 1.38 | 1.45 | 1.11 | |
Free Cash Flow |
(6.16) | (10.65) | (47.17) | (1.67) | |
Working Capital |
446.28 | 460.07 | 479.25 | 345.96 | |
Capital Expenditures |
0.00 | (0.34) | (0.57) | (0.48) | |
Net Current Asset Value |
417.72 | 429.62 | 443.46 | 310.80 | |
EV/EBIT |
2.00 | 1.58 | 0.97 | 0.00 | |
Capex to Sales |
0.00 | 0.02 | 0.03 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
13.26 | 15.18 | 38.56 | 14.09 | |
Average Payables |
5.04 | 8.44 | 9.89 | 5.23 | |
Average Inventory |
21.52 | 20.64 | 30.36 | 20.36 | |
Average Assets |
587.48 | 592.09 | 609.36 | 590.05 | |
Average Common Equity |
477.70 | 482.25 | 507.86 | 448.01 |
Columns are period end dates · fundamentals updated 5 Nov 2026